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Introduction
Sarcoidosis is a multi-systemic disorder whose cause 
is unknown. It commonly affects young and middle-aged 
adults, and is morphologically characterized by noncaseating 
epithelioid cell granulomas [1]. It often presents itself with 
bilateral hilar lymphadenopathy, pulmonary infiltration, and 
ocular and skin lesions.
Diagnosing sarcoidosis can be very challenging even for 
expert physicians, largely because of the lack of a diagnostic 
test for this disease, but also because of the multifaceted na-
ture of the disease, that often leads to a lack recognition and 
misdiagnosis of the condition.
This report reviews sarcoidosis’s clinical features, aspects 
of diagnosis, and treatment.
Diagnosis
An accurate diagnosis can be established when the fol-
lowing criteria are fulfilled: compatible clinico-radiological 
features supported by histological evidence of noncaseating 
epithelioid granulomas, and the exclusion of the known causes 
of granulomatous inflammation other than sarcoidosis [1]. 
Due to the large spectrum of other granulomatous diseases 
and the lack of a pathognomonic test, sarcoidosis is always a 
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Abstract
Sarcoidosis is a systemic granulomatous disease of unknown etiology that can affect virtually any organ, though there is clear predilection for the 
lungs and hilar lymph nodes.  Unfortunately, there is a great uncertainty in establishing the diagnosis of this disease due to lack of knowledge of the true 
cause of this condition, the absence of a pathognomonic test, and the close similarity with other granulomatous diseases. In the past decades several 
imaging techniques and laboratory tests have emerged, all meant to ensure not only an accurate diagnosis, but also to assess the activity, severity and 
extent of the disease. The treatment of sarcoidosis is also a subject of debate because of the disease’s ability to spontaneously resolve or to remain stable. 
In these conditions treatment is not always necessary.  This is why sarcoidosis is a great challenge in terms of diagnostic and management, even for expert 
physicians. The following report reviews the diagnostic aspects and approach to the treatment of sarcoidosis.
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Ведение пациентов с саркоидозом
Саркоидоз является системным гранулематозным заболеванием неизвестной этиологии, с возможностью поражения любых органов, в то 
же время преимущественно вовлекая легкие и корневые лимфатические узлы.  Неизвестность этиологии, отсутствие высоко специфических 
тестов и значительное сходство с другими гранулематозными заболеваниями, существенно затрудняют установление диагноза.  В последние 
десятилетия были внедрены новые радиологические и лабораторные методы исследования, призванные обеспечить не только точный диагноз, 
но и оценить активность, тяжесть и степень заболевания. Благодаря возможности болезни самоизлечиваться или иметь стабильное течение, 
лечение саркоидоза остается неоднозначной проблемой.Таким образом, диагностирование и лечение больных саркоидозом продолжает 
представлять трудности даже для опытных специалистов. В представленной статье проанализированы данные литературы касательно 
диагностики и лечения саркоидоза.
Ключевые слова: саркоидоз, диагностика, лечение, кортикостероиды.
diagnosis of exclusion. This is why these patients should be 
evaluated systemically, not only for establishing the diagnosis, 
but also for detecting other organs’ involvement. Moreover, 
the evaluation should provide information about whether the 
disease is stable or presents signs of progression, and if the 
patient will benefit from the indicated treatment [1].
The recommended approach to all patients suspected of 
sarcoidosis is to conduct a number of screening tests (tab. 1) 
in order to assess the extent and the severity of the disease.
Table 1
Recommended initial evaluation of patients with 
sarcoidosis
1. Comprehensive history (suggestive symptoms, family history, 
occupational/environmental exposure)
2. Physical examination – looking for various organ involve-
ment: lungs, eyes, skin, peripheral lymph nodes, heart, liver 
and spleen, neurological, etc
3. Chest X-ray (postero-anterior and lateral view), if necessary 
pulmonary HRCT
4. Pulmonary function tests: spirometry, lung volumes, DLCO
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5. Lab tests: CBC, blood calcium, liver enzymes (ALT, AST, 
alkaline phosphatase), blood urea, creatinine, ACE, ESR, urine 
analysis, 24 hours calcium excretion
6. ECG (if any abnormality –  investigate further with Holter 
ECG, EchoCG, cardiac MRI) 
7. Ophtalmologic  examination (slit lamp and fundoscopic eye 
examination)
8. Tuberculin test or IGRA, microscopy of the sputum for acid 
fast bacilli
9. Fiberoptic bronchoscopy with mucosal, transbronchial biop-
sy, BAL for CD4/CD8 ratio
10. Biopsy of extrapulmonary sites
HRCT – high resolution computerized tomography, DLCO – diffusion 
capacity for carbon monoxide, CBC – complete blood count, ALT – 
alanine aminotransferase, AST – aspartate aminotransferase, ACE 
– angiotensin converting enzyme, ESR – erythrocyte sedimentation 
rate, ECG – electrocardiogram, MRI – magnetic resonance imaging, 
BAL – bronchoalveolar lavage.
Modified from Costabel U., Hunnighake G.W., Ando M., Baughman R., 
Cordier J.F., du Bois R., et al., 
ATS/ERS/ WASOG Statement on sarcoidosis.SarcoidosisVasc Diffuse 
Lung Dis, 1999. 16: p. 149-173.
Clinical presentation 
Due to its multi-systemic nature, sarcoidosis has a wide 
variety of clinical symptoms. Several studies have reported 
that 30-50% of patients are asymptomatic at presentation 
[2]. This explains why the disease comes into attention when 
abnormalities are detected on a chest X-ray during a routine 
screening examination. Among patients who present symp-
toms, 20-30% have non-specific symptoms such as: fatigue, 
low grade fever, night sweats, weight loss and arthralgias [3]. 
While other patients present organ related symptoms: clinical 
signs of cardiac involvement occurs in less than 5%, sympto-
matic neurosarcoidosis < 10%, skin disease – 25-33% (fig. 1), 
ocular lesions in 10-90% of the cases, pulmonary symptoms 
(dry cough, dyspnea, chest dyscomfort) – 33-50% [1].
Natural course
The course and prognosis of sarcoidosis depend on the 
mode of onset and the spectrum of organ involvement. A 
recent debut and early course of the condition is defined as 
acute sarcoidosis [4]. However, the disease that persists longer 
than 2 years is defined as chronic sarcoidosis [5], which is 
characterized by its insidious onset, involvement of extrapul-
Fig. 1.  Cutaneous involvement in sarcoidosis.  Here is presented a wide variety of skin lesions caused by sarcoidosis: from simple isolated 
papules (A), to infiltrated extensive disfiguring plaques (B, C).
A C
B
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monary organs, and persistent or progressive pulmonary 
disease, which usually requires therapy [6]. 
However, there are standard clinical characteristics that 
have been found to play a consistent role in the prognosis 
of the disease. A good prognosis, is expected in presence of 
fever, erythema nodosum, and arthritis (Löfgren’s syndrome) 
[7]. On the other hand, age > 40 years, african ethnicity, the 
presence of lupus pernio, chronic uveitis, splenomegaly, bone 
lesions, neurosarcoidosis and myocardial involvement are all 
suggestive of poor prognosis [1].
Most patients with sarcoidosis have remission within 3 
years after diagnosis, which occurs either spontaneously or 
under treatment, with few or no consequences [8]. About 
one third of patients will have a stable chronic course, and 
a minority of them will show inexorable progression of the 
disease, leading to clinically significant organ impairment. 
Less than 5% of patients die from sarcoidosis due respiratory 
failure, cardiac or neurologic involvement [1].
Imaging
Chest X ray is the most widely used diagnostic tool. The 
chest radiograph is abnormal in more than 90% of sarcoidosis 
patients. In 50-85% of the cases symmetric hilar adenopathy 
is noted. Bilateral pulmonary infiltrates are seen in 25-60%, 
with a predilection for the upper lobes [9].
Several decades ago, a radiologic staging system for sar-
coidosis has been proposed. It included 5 stages: stage 0 – no 
pulmonary lesions (in patients with extrathoracic involve-
ment), stage I – bilateral hilar adenopathy, stage II – bilateral 
hilar adenopathy and pulmonary infiltrates, stage III – pul-
monary infiltrates, no adenopathy, and stage IV – pulmonary 
fibrosis. Radiological stages correlate with the severity of 
pulmonary dysfunction, and mortality rate [9]. These stages 
seem to have a predictive role in spontaneous remission rates. 
It was found that in stage I, spontaneous remission occurs in 
60-90% of cases, in stage II 40-70%, in stage III – in 20% of 
patients, and stage IV, due to fibrosis, no remission [6]. This 
is very important information when considering the decision 
to initiate treatment.
HRCT is a more accurate and reliable imagistic method, 
it often reveals more disease that it can be interpreted on a 
chest X-ray. Commonly, the imagistic pattern that defines 
pulmonary sarcoidosis is represented by nodules distributed 
in a perilymphatic manner [10] (fig. 2).
The pattern of distribution, upper lung predominance 
and coexistence of mediastinal lymphadenopathy strongly 
indicate the presence of sarcoidosis, helping distinguishing it 
from other nodular lesions such as eosinophilic granuloma, 
miliary tuberculosis, or metastasis [11].
Typical HRCT lesions include: peribronhovascular 
thickening, perilymphatic nodules, upper and mid-zone 
predominance, symmetric hilar lymph node enlargement, 
fibrotic changes with traction bronchiectasis, and parenchy-
mal distortion [12] (fig. 3: A, B). Although typical radiological 
lesions can easily be recognized, sarcoidosis can mimic a large 
variety of other lung diseases. Knowing its atypical features is 
Fig. 2.  HRCT appearance of pulmonary sarcoidosis. Nodules are the hallmark of sarcoidosis.  They are typically distributed in a perilym-
phatic manner. HRCT can show a large variety of these nodules: from very fine, poorly defined nodules (A, B), accompanied by diffuse 
ground glass attenuation (A, B), to septal reticulation (arrows, B) and bilateral hilar adenopathy (A, B), to larger nodules with ill defined 
margins (C, D).
A
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important for identifying sarcoidosis. Uncommon HRCT fea-
tures include: pleural involvement, cavitation, patchy ground 
glass opacities, alveolar sarcoidosis, milliary pattern, unilateral 
disease, and aspergilloma [12] (fig. 3: C, D).
Although HRCT is superior to the chest X-ray in detecting 
pulmonary sarcoidotic lesions, there is insufficient evidence 
that CT has a clinical role in the management of pulmonary 
sarcoidosis [1].
MRI with gadolinium enhancement is another imaging 
technique particularly useful in detecting cardiac and neu-
rological involvement [13].
Pulmonary function tests (PFT)
Often in sarcoidosis pulmonary function tests are within 
the lower limit of the normal range. Winterbauer and col-
legues found a correlation between the radiological stage 
and abnormal PFT. Thus, in patients with no evidence of 
radiologic parenchymal lesions, the vital capacity, DLCO, 
and lung compliance are abnormal in 20-40% of cases. In 
contrast, in those with parenchymal radiological lesions, PFTs 
are abnormal in 50-70% of cases. The most severe pulmonary 
function impairment is registered in patients with stage IV 
sarcoidosis [14].
Although commonly thought of as a restrictive lung dis-
ease, airway obstruction has become a recognized feature of 
sarcoidosis in the past years. This phenomenon is explained 
by the involvement of the granulomatous endobronchial, or 
airway distortion from parenchymal disease, stenosis, or air-
way reactivity [15]. Depending on the case definition, airway 
obstruction from sarcoidosis has been reported in a broad 
range from 4 to 63% of cases [16]. Viskum et al. reported that 
sarcoidosis patients with FEV1/FVC < 70% had increased 
mortality compared to those with FEV1/FVC ≥ 70% [17].
Bronchoalveolar lavage (BAL)
At the time of diagnosis, 90% of sarcoidosis patients show 
an increased number of lymphocytes found in the BAL fluid 
[18]. Most researchers agree that the BAL CD4/CD8 ratio > 3.5 
shows high specificity for a sarcoidosis diagnosis (93-96%), al-
though the sensitivity is low, 53-59% [19]. No parameter from 
the BAL cells profile is significant alone for the differentiation 
of other interstitial lung diseases, but a combination of them. 
Thus, if the BAL fluid analysis shows a normal or slightly el-
evated total cell count, with elevated number of lymphocytes, 
abnormal percentage of eosinophils and neutrophils, and no 
“foamy” alveolar macrophages or plasma cells – the most likely 
diagnosis is sarcoidosis [1].
Morphologic confirmation
Traditionally, a biopsy is needed for the definitive diagnosis 
of sarcoidosis [1]. However, certain clinical presentations are 
so specific for sarcoidosis, that the diagnosis can be accepted 
without a biopsy. Examples of these include Löfgren’s syn-
drome (fever, erythema nodosum, arthralgias, and bilateral 
hilar adenopathy), and Heerfordt’s syndrome (fever, parotid 
gland enlargement, facial palsy, and anterior uveitis) [1].
In all other cases, a biopsy specimen should be obtained 
from the involved organ that is most easily accessed, such as 
enlarged peripheral lymph nodes, skin, etc. Also, it is wise 
to select the least invasive method to confirm the suspected 
diagnosis.
Hilar lymph nodes and the lungs are the most frequent 
Fig. 3.  Typical and atypical HRCT appearance of pulmonary sarcoidosis.
Image A and B show typical findings with upper lobe predominance (A) ill defined nodules with 
a peribronchovascular distribution, as well as parenchymal distortion and large fibrotic lesions 
in the middle perihilar zone (B).  Image C and D demonstrate atypical HRCT findings such as 
alveolar sarcoidosis (C) characterized by a zone of parenchymal consolidation with or without 
air bronchogram (arrows); and lower lobe “honey-combing” and traction bronchiectasis (D) 
in a biopsy-confirmed sarcoidosis patient.
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affected organs in sarcoidosis [4]. This is why bronchoscopy 
and the biopsy techniques applied during this procedure are 
of great help in confirming the diagnosis. The endobron-
chial biopsy has a sensitivity of 40-60%. Supplemented by the 
transbronchial lung biopsy, the diagnostic yield is increased 
to 90%. Moreover, the addition of endobronchial ultrasound 
guidance increases the accuracy and success rate in the biopsy 
of mediastinal lymph nodes [9]. Of course, if none of these 
procedures are revealing, mediastinoscopy and surgical lung 
biopsy may be suggested.
Difficulties in establishing the diagnosis may arise if 
patients refuse biopsy, or if lung biopsy is considered to 
be a high risk. In these cases, clinical and radiological fin-
dings should be considered [1]. Researchers found that the 
reliability of these criteria is inversely correlated with the 
radiological stage. Thus, compatible clinical and radiological 
findings have a high accuracy in radiological stage I (98%), 
good diagnostic reliability in stage II (89%), and less reliable 
in stage III (52%) or stage 0 (23%) of sarcoidosis. Therefore, 
histological confirmation may not be needed in asymptomatic 
patients with symmetric hilar adenopathy. However, when 
hilar adenopathy is asymmetric, massive, or associated with 
large paratracheal enlargement, morphologic confirmation is 
strongly recommended [4].
Assessing disease activity and extent
Nowadays, there are several available techniques used for 
the evaluation of activity and stage of sarcoidosis. Neverthe-
less, clinical indices remain the cornerstone in evaluating 
disease activity and severity [1]. Thus, the presence of systemic 
symptoms such as uveitis, hypercalcemia, active skin lesions, 
enlarged parotid and salivary glands, enlarged liver and spleen, 
myocardial disease, neurosarcoidosis, and progressive respira-
tory symptoms, are indicative of activity of the disease [7]. 
A long list of biochemical studies have been proposed for 
activity evaluation. In practice, only a few of them have been 
assessed systematically. The most widely used biochemical 
marker is the serum angiotensin converting enzyme (ACE), 
which is produced by activated epithelioid cells and mac-
rophages at sites of inflammation. This is why serum ACE 
level is thought to reflect the total body granuloma burden in 
sarcoidosis. However several studies suggest that its activity 
assessment’s usefulness is questionable [20]. These researches 
showed no correlation of ACE levels with the disease activity 
in the lungs (intensity of lymphocityc alveolitis). Neverthe-
less, measuring ACE levels seems to be useful in monitoring 
the treatment effect, since increased serum ACE activity will 
reduce in a short time after the start of corticosteroid treat-
ment [4].
More than 20 years ago it was stipulated that the quanti-
fication of BAL lymphocytes provide a sensitive and specific 
means of assessing the activity of the disease in the lungs, 
however it has little clinical application in patient care. Gal-
ium scans have been valuable in detecting active granulomas, 
and fluordeoxyglucose positron emission tomography (FDG 
PET) has proven to be even more accurate [21]. These two 
techniques are useful tools not only in assessing activity, but, 
due to their high sensitivity in detecting the loci of inflam-
mation, have also shown beneficial in looking at the extent of 
the disease. Of course, in terms of deciding whether to initiate 
treatment or not, assessing the extent and the severity of the 
disease becomes more important. However, in patients with 
radiological stage IV, with CT signs of pulmonary fibrosis, 
identifying the presence of residual active reversible lesions 
in a background of fibrosis provides valuable information that 
could serve as a guide for treatment [1].
Nevertheless, with the advanced imaging technology that 
is commonly nowadays available, in routine clinical practice, 
disease activity is assessed based on clinical findings: the 
mode of onset of the disease, the worsening or persistence of 
symptoms, the presence of skin lesions, progressive changes 
on chest radiographs, and pulmonary function tests [1].
Differential diagnosis
In most diseases, there is a morphological pattern that de-
fines the condition, making a histological examination play the 
role of the ultimate investigation. Unfortunately, sarcoidosis is 
an exception. Sarcoidotic granulomas have no unique histo-
logical features to differentiate them from other granulomas, 
such as those from: tuberculosis, atypical mycobacteriosis, 
mycoplasma infections, fungal granuloma (aspergillosis, 
histoplasmosis, cryptococcosis, coccidioidomycosis, blas-
tomycosis), drug reactions, aspiration of foreign material, 
hypersensitivity pneumonitis, pneumoconiosis (beryllium, 
aluminium, titanium), lymphocytic interstitial pneumonia, 
necrotizing sarcoid granulomatosis (NSG), pneumocystis 
carinii, Wegener’s granulomatosis, lymphoma (especially in 
the lymph nodes), toxoplasmosis, etc. [1].
Exclusion of other causes of granulomatous inflammation 
requires special stains for acid-fast bacilli and fungi, as well as 
cultures for these organisms. The presence of necrotic lesions 
in the biopsy specimen requires further investigations for my-
cobacteria, fungi, other potential pathogens, and vasculitis [1].
Despite the imposing list of other granulomatous diseases, 
a chest X-ray demonstrating a bilateral hilaradenopathy 
will considerably reduce the list of differential diagnosis to 
sarcoidosis, lymphoma, tuberculosis, and fungal infections. 
Statistic data from a study conducted in USA revealed that 
99,95% of patients with bilateral hilar adenopathy who un-
derwent mediastinoscopy were diagnosed with sarcoidosis, 
8 persons out of 33,000 with tuberculosis, 9 – with Hodgkin’s 
lymphoma, and one with non-Hodgkin’s disease [22]. Cer-
tainly, local investigations and adjustments upon the incidence 
of these diseases are needed, especially in tuberculosis high 
burden countries. 
Treatment
Indications for treatment
Because the majority of patients with sacoidosis will 
undergo spontaneous remission, indications for treatment 
remain a controversial subject. Moreover, due to consider-
able side effects of corticosteroids and higher relapse rates, 
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the initiation of systemic treatment should be done after a 
careful evaluation of compatible criteria.
There is a general rule that patients with potential danger-
ous diseases must be treated [1]. Although the indications for 
initiating treatment in cases of life threatening organ damage 
are more or less clear, there is much confusion about when to 
start treatment in pulmonary involvement. Due to high rates 
of spontaneous remission in earlier radiological stages, there 
is a common opinion not to treat asymptomatic patients with 
no or mild functional disturbances [1]. Instead, they should 
be followed-up at 6 months intervals for stage I, and every 3 
months for the other stages [1, 4]. During the follow up period, 
patients who are worsening will be initiated for treatment 
immediately [1]. This way, patients who improved without 
treatment will be spared of corticosteroid’s toxicity. Finally, 
there is no unanimous recommendation about patients who 
neither improve nor worsen during a period of 6 months of 
follow up. Some experts suggest they should be given a corti-
costeroid trial, or simply be monitored further [23].
Patients with excellent prognosis (Löfgren’s syndrome) 
will be also closely observed, and will benefit, if necessary, 
from palliative treatment (NSAIDs for fever and arthralgias, 
bronchodilators and inhaled corticosteroids for cough and 
wheezing), or, in severe cases, short term systemic corticos-
teroids [23].
Regarding patients with symptomatic pulmonary disease 
with signs of clinical and radiological progression, most clini-
cians feel that they will require therapy [1], as well as do those 
who present severe pulmonary symptoms and pulmonary 
dysfunction [24]. Other candidates for systemic treatment are: 
asymptomatic patients with moderate to severe alterations of 
pulmonary function, most patients in stage III of sarcoidosis, 
and patients with stage IV with irreversible fibrosis and signs 
of co-existence of active alveolitis [1].
Inactive stage IV patients have shown to respond poorly 
to systemic corticosteroids, but the symptoms they com-
monly complain could be due to complications such as: 
bronchiectasis, haemoptysis, and aspergiloma, which are 
generally treated with antibiotics and antifungal agents [25]. 
Patients in stage IV with extensive fibrosis are candidates for 
lung transplantation [1].
In some cases, the pulmonary involvement is not severe 
enough to motivate the need for the initiation of treatment, 
but concomitant extrapulmonary disease can make it indi-
cated. The decision to treat extrapulmonary sarcoidosis will 
be based on the organ involved and its degree of impairment, 
assessed by clinical and laboratory examinations [26]. Thus, 
cardiac involvement, neurosarcoidosis, eye lesions that are not 
responsive to local treatment, persistent renal impairment, hy-
percalcemia unresponsive to dietary measures, liver dysfunc-
tion with cholestatic symptoms, impaired synthetic function, 
or portal hypertension; splenomegaly with hypersplenism 
[26], diffuse or disfiguring skin lesions not responsive to topic 
treatment, chronic myopathy, weight loss, or severe fatigue[1, 
4] will benefit from systemic corticosteroids. 
Medication
Corticosteroids
Corticosteroids are the first-choice drugs in the treatment 
of sarcoidosis [24]. In mild cases, improvement can be reached 
by using only topic corticosteroids [1]. These include corticos-
teroid creams (e.g.: for isolated mild skin lesions), intralesional 
injections (for skin lesions, localized upper respiratory tract 
lesions), drops (in case of anterior uveitis), and sprays (for 
cough and wheezing) [26]. Systemic treatment is preferred 
to topical in treating refractory lesions and in the cases that 
were elucidated earlier in the Indications for treatment chapter.
Several studies performed in the past decades have re-
ported that systemic corticosteroids improve symptoms, chest 
X-ray findings, and functional tests [27-29], although the fact 
that they are associated with a higher relapse rate within 2 
years after treatment cessation [28, 30-32].
While the optimal doze and duration of treatment has not 
been standardized through randomized trials, treatment of 
pulmonary sarcoidosis is commonly initiated with a 0.5 mg/
kg/day (20-40mg) prednisone or equivalent [33] for a period 
of 1-3 months. Cases of neurosarcoidosis and myocardial 
might need higher doses (1 mg/kg/day) [34, 35].
In cases of positive response after a reevaluation, the dose 
of corticosteroids should be slowly tapered to a daily mainte-
nance dose of 5-10 mg, and continue treatment for at least 1 
year [1]. Patients who failed to respond after a period of 3-6 
months of treatment, tend to present a chronic evolution. 
These patients may need lifelong treatment of corticosteroid, 
administrated at the lowest effective dose [1]. 
Alternative treatment
Patients who require long term administration of corti-
costeroids, should benefit the treatment with corticosteroid 
sparing agents [1]. Usually they demonstrate a lower efficacy, 
and necessitate a longer period of administration to reach 
their maximum potency. More commonly, these drugs are 
used in combination with a low dose of corticosteroids [23].
Among cytotoxic agents, the most widely used are metho-
trexate and azathioprine. There are several studies where 
these drugs were used for chronic sarcoidosis, either alone 
or in combination with prednisone. They seem to be safe 
and efficient, although treatment with either azathioprine 
or methotrexate is associated with high relapse rates after 
discontinuation [36].
Antymalarial agents such as chloroquine and hidroxy-
chloroquine have proved efficacy in disfiguring skin lesions 
(lupus pernio), in hypercalcemia and neurosarcoidosis [37]. 
Because of increased risk of retinopathy, chlorochine has a 
limited use, in contrast to hydroxychlorochine, which has 
not demonstrated such serious side-effects [38]. Moreover, 
hydroxychlorochine is preferred as treatment for diabetic 
patients with mild to moderate sarcoidosis, due to its positive 
effects in carbohydrate metabolism [39].
Recently, Infliximab, Thalidomide and Pentoxiphylline 
have demonstrated some efficacy in various forms of treat-
ment for sarcoidosis [4].
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Follow up
As it was previously stated, patients with stage I sarcoidosis 
should be evaluated every 6 months, and every 2-3 months 
for all other stages [1]. Patients require evaluation for altera-
tions in the physiologic function of the involved organs, in 
comparison with the initial investigation, [1]. New symptoms 
demand further investigations [1]. And of course, due to the 
toxicity of the drugs used for treatment, tests should be per-
formed to assess any possible side effects.
After discontinuation of therapy, it is suggested that pa-
tients be monitored for a period of 3 years [1].
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